Evidence map›Paper›PMID 26673823›Full record

ArticleOncotarget2015

Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma.

David J Duffy, Aleksandar Krstic, Melinda Halasz, Thomas Schwarzl, Dirk Fey, Kristiina Iljin, Jai Prakash Mehta, Kate Killick, Jenny Whilde, Benedetta Turriziani and 8 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Oxphos targeting ofFrontiers in oncology · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Nucleic acid therapeutics · 2020
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Neuroblastoma, a Paradigm for Big Data Science in Pediatric Oncology.International journal of molecular sciences · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 4 countries.

David J DuffySystems Biology Ireland, University College Dublin, Belfield, Dublin, Ireland.
Aleksandar KrsticSystems Biology Ireland, University College Dublin, Belfield, Dublin, Ireland.
Melinda HalaszSystems Biology Ireland, University College Dublin, Belfield, Dublin, Ireland.
Thomas SchwarzlSystems Biology Ireland, University College Dublin, Belfield, Dublin, Ireland.
Dirk FeySystems Biology Ireland, University College Dublin, Belfield, Dublin, Ireland.
Kristiina IljinVTT Technical Research Centre of Finland, Espoo, Finland.
Jai Prakash MehtaSystems Biology Ireland, University College Dublin, Belfield, Dublin, Ireland.
Kate KillickSystems Biology Ireland, University College Dublin, Belfield, Dublin, Ireland.
Jenny WhildeSystems Biology Ireland, University College Dublin, Belfield, Dublin, Ireland.
Benedetta TurrizianiSystems Biology Ireland, University College Dublin, Belfield, Dublin, Ireland.
Saija Haapa-PaananenVTT Technical Research Centre of Finland, Espoo, Finland.
Vidal FeyVTT Technical Research Centre of Finland, Espoo, Finland.
Matthias FischerDepartment of Paediatric Haematology and Oncology and Center for Molecular Medicine Cologne (CMMC), University Hospital Cologne, Cologne, Germany.
Frank WestermannDivision of NB Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Kai-Oliver HenrichDivision of NB Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Steffen BannertDivision of NB Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Desmond G HigginsSystems Biology Ireland, University College Dublin, Belfield, Dublin, Ireland.
Walter KolchSystems Biology Ireland, University College Dublin, Belfield, Dublin, Ireland.
University College Dublin · IEHeidelberg University · DEVTT Technical Research Centre of Finland · FIGerman Cancer Research Center · DETieto (Finland) · FIUniversity Hospital Cologne · DEUniversity of Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite intensive study, many mysteries remain about the MYCN oncogene's functions. Here we focus on MYCN's role in neuroblastoma, the most common extracranial childhood cancer. MYCN gene amplification occurs in 20% of cases, but other recurrent somatic mutations are rare. This scarcity of tractable targets has hampered efforts to develop new therapeutic options. We employed a multi-level omics approach to examine MYCN functioning and identify novel therapeutic targets for this largely un-druggable oncogene. We used systems medicine based computational network reconstruction and analysis to integrate a range of omic techniques: sequencing-based transcriptomics, genome-wide chromatin immunoprecipitation, siRNA screening and interaction proteomics, revealing that MYCN controls highly connected networks, with MYCN primarily supressing the activity of network components. MYCN's oncogenic functions are likely independent of its classical heterodimerisation partner, MAX. In particular, MYCN controls its own protein interaction network by transcriptionally regulating its binding partners.Our network-based approach identified vulnerable therapeutically targetable nodes that function as critical regulators or effectors of MYCN in neuroblastoma. These were validated by siRNA knockdown screens, functional studies and patient data. We identified β-estradiol and MAPK/ERK as having functional cross-talk with MYCN and being novel targetable vulnerabilities of MYCN-amplified neuroblastoma. These results reveal surprising differences between the functioning of endogenous, overexpressed and amplified MYCN, and rationalise how different MYCN dosages can orchestrate cell fate decisions and cancerous outcomes. Importantly, this work describes a systems-level approach to systematically uncovering network based vulnerabilities and therapeutic targets for multifactorial diseases by integrating disparate omic data types.

Indexed as

Blotting, WesternChromatin ImmunoprecipitationComputational BiologyGene Expression Regulation, NeoplasticGenes, mycHigh-Throughput Nucleotide SequencingHumansNeuroblastomaN-Myc Proto-Oncogene ProteinNuclear ProteinsOligonucleotide Array Sequence AnalysisOncogene ProteinsPolymerase Chain ReactionProtein Interaction MapsProteomicsSignal TransductionMYCN protein, humanN-Myc Proto-Oncogene ProteinNuclear ProteinsOncogene Proteins4sU-seqmRNA sequencing (mRNA-seq)MYC (c-MYC)neuroblastomatranscriptional regulation

Identifiers

PMID26673823
PMCPMC4791225
OpenAlexW2190425936

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.